Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,179.4
-1.8 (-0.06%)

 

  • STI Straits Times Index
    3,179.4
    -1.8 (-0.06%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,550.9
    -0.7 (-0.05%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    27,149.6
    -790.8 (-2.83%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,976.5
    -84.2 (-2.75%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,379.4
    163.7 (0.71%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,105.4
    -5.8 (-0.09%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,185.3
    8.6 (0.39%)
    Index delayed 20 minutes
  • XAO XAO
    7,135.9
    37.5 (0.53%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,113.7M
  • Value: 704.3M
  • Rise: 180
  • Fall: 140
  • Unch: 496

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Medtecs Intl0.187+0.015
Healthway Med0.044-0.002
AsiaMedic0.017-
UG Healthcare0.345+0.095
Golden Agri-Res0.215-0.010
Thomson Medical0.063-
Rex Intl0.174+0.006
MarcoPolo Marine0.022+0.001
Genting Sing0.870-0.005
Ntegrator Intl0.011-

World Indices

World Indices
Name Last Change
Nasdaq 9,269.7 +130.4
HSI 27,157.7 -782.8
HSCEI 10,605.2 -364.1
Jakarta 6,106.9 -4.3
Nikkei 225 23,379.4 +163.7
SSE Comp 2,976.5 -84.2
Shanghai A 3,118.9 -88.2
Shanghai B 248.6 -8.9
PSE Comp 0.0
KOSPI 2,185.3 +8.6

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

GALAPAGOS NV SPON ADR REPR 1 ORD SHS GALAPAGOS NV SPON ADR REPR 1 ORD SHS
Updated on 28 Jan 2020 (End of trading day)
Last (USD): 230.280 Change: +3.010 High: 231.940 Remarks: -
Change (%): +1.32 Low: 228.830
Open 229.610 Yesterday's Close 227.27
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 121,211 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.53379 Trailing EPS (USD) e 4.79935 NAV (USD) b 42.7415
PE a - Trailing PE f 47.981 Price / NAV b 5.3877
Dividend (USD) d - Cash In Hand (USD) g 79.2486 Issued & Paid-up Shares c 64,667,000
Dividend Yield (%) d - Price / Cash In Hand g 2.906 Treasury Shares h -
Beta - 75 Daysi 1.537 R-Squared - 75 Days(%)i 9.35 Market Cap (M) 14,891.517
Beta - 500 Daysi 0.005 R-Squared - 500 Days (%)i - Enterprise Value (M) 8,813.788
Piotroski F Score 2 Exchange Code GLPG Par Value ( $ ) n.a.
52 Weeks Volatility (%) 39.45 Free Float (%) 95.3
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 29 Nov 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 17 Sep 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference GALAPAGOS NV SPON ADR REPR 1 ORD SHS NASDAQ 14,891.517 - 47.981 5.3877 -
Industry Biotechnology NASDAQ 2,348.378 361.842 92.382 5.8406 0.755
Local Peer AMGEN INC NASDAQ 133,596.331 15.916 16.561 12.2263 2.488
Local Peer GILEAD SCIENCES INC NASDAQ 81,425.054 14.927 30.236 3.9519 3.590
Local Peer VERTEX PHARMACEUTICAL NASDAQ 59,651.086 28.454 27.825 11.3548 -
Local Peer BIOGEN INC NASDAQ 50,875.622 11.483 9.429 3.6350 -
Local Peer ILLUMINA INC NASDAQ 46,199.160 55.931 47.481 10.4076 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 37,778.597 15.455 17.619 3.5965 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 23,671.498 305.045 16.100 2.2833 -
Local Peer SEATTLE GENETICS INC NASDAQ 19,354.621 - - 10.8758 -
Local Peer INCYTE CORPORATION NASDAQ 16,469.255 150.414 40.668 6.7984 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 15,427.991 - - 5.0182 -
Local Peer ALNYLAM PHARMACEUTICALS INC NASDAQ 12,790.133 - - 7.9586 -
Local Peer EXACT SCIENCES CORP NASDAQ 13,355.415 - - 17.8482 -
Other Local Peers BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), 10X GENOMICS INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), MODERNA INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), EXELIXIS INC (NASDAQ), REPLIGEN CORP (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), FIBROGEN INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), NATERA INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), ALKERMES PLC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), UNIQURE N.V. (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), VIELA BIO INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), ARVINAS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), EPIZYME INC (NASDAQ), XENCOR INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), ALECTOR INC (NASDAQ), INSMED INC (NASDAQ), REGENXBIO INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), CORTEXYME INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), NEXTCURE INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), OPKO HEALTH INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), DERMIRA INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), XBIOTECH INC (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), INTREXON CORP (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), OMEROS CORP (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), CYTOKINETICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), RETROPHIN INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), ARDELYX INC (NASDAQ), AVROBIO INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), NANTKWEST INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), KURA ONCOLOGY INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), AGENUS INC (NASDAQ), MACROGENICS INC (NASDAQ), MERUS B V (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), COMPUGEN (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), CABALETTA BIO INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), ANAPTYSBIO INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), IVERIC BIO INC (NASDAQ), PERSONALIS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), NOVAVAX INC (NASDAQ), GERON CORP (NASDAQ), MEDICINOVA INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), KAMADA (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), ATHERSYS INC (NASDAQ), IMV INC (NASDAQ), AFFIMED N V (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), XOMA CORP (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), CHIASMA INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), ARAVIVE INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), VERASTEM INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), SAVARA INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), VACCINEX INC (NASDAQ), CHIMERIX INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), OTONOMY INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), ORGENESIS INC (NASDAQ), SESEN BIO INC (NASDAQ), EQUILLIUM INC (NASDAQ), TREVENA INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), INFLARX N V (NASDAQ), SYNLOGIC INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), VERMILLION INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), SOLIGENIX INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), CURIS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), INMUNE BIO INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), RESTORBIO INC (NASDAQ), ADVAXIS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), ZAFGEN INC (NASDAQ), EVOGENE LTD (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), BIOCARDIA INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), OCUGEN INC (NASDAQ), VAXART INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), SOPHIRIS BIO INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), ATYR PHARMA INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), TROVAGENE INC (NASDAQ), PRECIPIO INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), TOCAGEN INC (NASDAQ), BIOCEPT INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), SENESTECH INC (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), OPGEN INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), SPHERIX INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ)
Global Peer CSL ASX 141,910.746 52.894 52.894 18.9640 0.849
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer AGILENT TECHNOLOGIES INC NYSE 27,041.754 85.575 25.249 5.6954 0.701
Global Peer SINO BIOPHARM HKEx 139,336.513 13.004 13.496 4.1496 0.660
Global Peer WUXI BIO HKEx 131,906.697 176.604 138.064 13.5781 -
Global Peer BEIGENE HKEx 95,161.500 - - 9.4948 -
Global Peer Lonza SGX 5,937.453 6.613 6.613 0.6568 4.787
Global Peer GENSCRIPT BIO HKEx 34,445.447 207.146 - 9.7137 -
Global Peer 3SBIO HKEx 26,669.685 17.630 21.458 2.6286 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 2,878.038 45.902 669.311 2.7807 -
Other Global Peers ALPHAMAB-B (HKEx), HAOHAI BIOTEC (HKEx), POLYNOVO LIMITED (ASX), MYOVANT SCIENCES LTD (NYSE), MESOBLAST LTD (ASX), FRONTAGE (HKEx), CKLIFE SCIENCES (HKEx), NANOVIRICIDES INC (NYSE American), AVITA MEDICAL LTD (ASX), VIVA BIOTECH (HKEx), ASCENTAGE-B (HKEx), KADMON HLDGS INC (NYSE), SINOMAB BIO-B (HKEx), ARCUS BIOSCIENCES INC (NYSE), ASCLETIS-B (HKEx), ESSEX BIO-TECH (HKEx), LEE'S PHARM (HKEx), DPHARMA (Bursa), NEXT SCIENCE LTD (ASX), PFENEX INC (NYSE American), TELIX PHARMACEUTIC (ASX), BBI LIFE SCI (HKEx), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), NEUREN PHARMACEUTICALS LTD (ASX), LINEAGE CELL THERAPEUTICS INC (NYSE American), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), UNI-BIO GROUP (HKEx), RESAPP HEALTH LIMITED (ASX), CEL-SCI CORP (NYSE American), PYC THERAPEUTICS LIMITED (ASX), ENZO BIOCHEM INC (NYSE), 22ND CENTURY GROUP INC (NYSE American), PALATIN TECHNOLOGIES INC (NYSE American), IMUGENE LIMITED (ASX), CYNATA THERAPEUTICS LTD (ASX), IMMUTEP LTD (ASX), ONCOSIL MEDICAL LIMITED (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), ORTHOCELL LIMITED (ASX), CT ENTERPRISE (HKEx), ISORAY INC (NYSE American), INVEX THERAPEUTICS LTD NPV (ASX), BIOSINO BIO-TEC (HKEx), BIOTRON (ASX), GENETIC TECHNOLOGIES (ASX), KAZIA THERAPEUTICS LIMITED (ASX), ACTINOGEN MEDICAL LTD (ASX), ARMATA PHARMACEUTICALS INC (NYSE American), REGENT PACIFIC (HKEx), ANTEOTECH LIMITED (ASX), BIONOMICS LTD (ASX), MEMPHASYS LTD (ASX), TALI DIGITAL LIMITED (ASX), IBIO INC (NYSE American), EXTRAWELL PHAR (HKEx), CCP TECHNOLOGIES LTD (ASX), ORAGENICS INC (NYSE American), RHINOMED LIMITED (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), ACTINIUM PHARMACEUTICALS INC (NYSE American), PROTEOMICS INTL LABORATORIES LTD (ASX), IMMURON LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), CELLMID LIMITED (ASX), PATRYS LIMITED (ASX), Suntar Eco-City^ (SGX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), REGENEUS LTD (ASX), ADALTA LTD (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), HOLISTA COLLTECH LIMITED (ASX), ANATARA LIFESCIENCES LTD (ASX), SIENNA CANCER DIAGNOSTICS LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), AIM IMMUNOTECH INC (NYSE American), LIVING CELL TECHNOLOGIES (ASX), HAO WEN HLDGS (HKEx), BENITEC BIOPHARMA LTD (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), BIOXYNE LIMITED (ASX), MEDIBIO LIMITED (ASX), QT Vascular (SGX), MGRC (Bursa), TBG DIAGNOSTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), BPH ENERGY LIMITED (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --5.220
-2.22 %
10 Days -+12.400
+5.69 %
20 Days -+23.450
+11.34 %
Medium Term Return 3 Months -+45.100
+24.35 %
6 Months -+56.880
+32.80 %
1 Year -+129.090
+127.57 %
Long Term Return 2 Years -+112.060
+94.79 %
3 Years -+163.040
+242.47 %
Annualised Return Annualised --
+50.73 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 94.750 - 242.375 Change From 1 Year Low +135.530 % Change From 1 Year Low (%) +143.04
Change From 1 Year High -12.095 % Change From 1 Year High (%) -4.99
2 Years Range 85.000 - 242.375 Change From 2 Years Low +145.280 % Change From 2 Years Low (%) +170.92
Change From 2 Years High -12.095 % Change From 2 Years High (%) -4.99
5 Years Range 37.030 - 242.375 Change From 5 Years Low +193.250 % Change From 5 Years Low (%) +521.87
Change From 5 Years High -12.095 % Change From 5 Years High (%) -4.99
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Historical Price Data

Date Open High Low Close Volume VWAP
28 Jan 2020 229.610 231.940 228.830 230.280 121,211 -
27 Jan 2020 227.570 229.060 226.520 227.270 103,095 -
24 Jan 2020 237.800 238.433 231.140 231.360 184,600 -
23 Jan 2020 236.240 236.240 232.020 232.100 142,300 -
22 Jan 2020 236.960 238.220 235.300 235.500 161,620 -
21 Jan 2020 237.740 242.375 237.180 238.680 296,116 -
17 Jan 2020 228.140 229.860 227.250 227.690 142,951 -
16 Jan 2020 222.850 227.330 222.720 226.150 327,467 -
15 Jan 2020 215.490 218.890 215.080 217.880 116,574 -
14 Jan 2020 209.970 212.620 209.210 211.730 115,359 -
13 Jan 2020 212.020 212.560 208.200 208.220 200,965 -
10 Jan 2020 212.560 215.200 212.220 212.560 108,464 -
09 Jan 2020 210.090 212.240 209.820 210.650 71,973 -
08 Jan 2020 206.370 207.570 206.070 206.720 72,210 -
07 Jan 2020 207.100 207.800 205.800 206.800 82,859 -
06 Jan 2020 205.280 206.260 204.700 206.260 71,566 -
03 Jan 2020 207.550 211.150 207.550 209.080 63,947 -
02 Jan 2020 211.020 212.310 209.470 212.090 131,845 -
31 Dec 2019 207.830 208.880 206.010 206.830 113,491 -
30 Dec 2019 209.200 209.540 208.180 208.600 71,269 -
27 Dec 2019 210.170 210.430 209.160 209.360 61,541 -
26 Dec 2019 209.560 210.475 209.000 209.180 40,431 -
Summary
Current 2 Weeks
(14 Jan 2020 to 28 Jan 2020)
209.970 242.375 209.210 230.280 1,711,293 -
Previous 2 Weeks
(30 Dec 2019 to 13 Jan 2020)
209.200 242.375 208.180 208.220 988,589 -
4 Weeks from
(29 Nov 2019 to 27 Dec 2019)
196.500 242.375 195.810 209.360 2,704,898 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.